Skip to main content

Cancer drug development company joins QM’s Innovation Centre

The Queen Mary BioEnterprises (QMB) Innovation Centre, London’s first completely new build facility for early stage start-up and follow on life sciences and biotechnology companies, has announced the chemistry division of Spirogen, a drug development company developing novel cancer therapies, as their newest tenant.

Published on:

Related items

For media information, contact:

Rupert Marquand
Media Relations Manager
Back to top